Publications by authors named "Paul V McGuirt"
Purpose: This phase I study was conducted to determine the dose-limiting toxicity (DLT), maximum-tolerated doses, and recommended phase II doses of the combination of weekly intravenous paclitaxel and oral eniluracil/5-fluorouracil (5-FU).
Patients And Methods: Patients received paclitaxel i.v.
Article Synopsis
- The study aimed to compare the effectiveness and tolerability of eniluracil/fluorouracil (EU/5-FU) versus fluorouracil/leucovorin (5-FU/LV) as first-line treatments for advanced colorectal cancer.
- A total of 981 patients participated, with findings showing that EU/5-FU had a median survival of 13.3 months compared to 14.5 months for 5-FU/LV, indicating that while the treatments were comparable, EU/5-FU did not demonstrate statistical equivalence in overall survival.
- Both treatments were well tolerated, but EU/5-FU resulted in inferiority in progression-free survival, while showing lower rates of severe granul